Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 14 03:43PM ET
137.59
Dollar change
-0.86
Percentage change
-0.62
%
IndexNDX, S&P 500 P/E12.30 EPS (ttm)11.19 Insider Own0.75% Shs Outstand145.72M Perf Week-2.66%
Market Cap20.14B Forward P/E8.52 EPS next Y16.15 Insider Trans-0.05% Shs Float144.63M Perf Month-2.42%
Income1.63B PEG14.47 EPS next Q3.61 Inst Own88.89% Short Float2.59% Perf Quarter-18.24%
Sales9.38B P/S2.15 EPS this Y-2.48% Inst Trans4.14% Short Ratio2.48 Perf Half Y-31.41%
Book/sh112.28 P/B1.23 EPS next Y0.53% ROA5.95% Short Interest3.74M Perf Year-39.30%
Cash/sh16.23 P/C8.48 EPS next 5Y0.85% ROE10.36% 52W Range128.51 - 238.00 Perf YTD-10.03%
Dividend Est.- P/FCF10.34 EPS past 5Y-18.67% ROI7.56% 52W High-42.19% Beta0.01
Dividend TTM- Quick Ratio0.90 Sales past 5Y-5.07% Gross Margin75.38% 52W Low7.06% ATR (14)4.40
Dividend Ex-Date- Current Ratio1.35 EPS Y/Y TTM39.71% Oper. Margin23.46% RSI (14)39.71 Volatility3.70% 2.74%
Employees7570 Debt/Eq0.40 Sales Y/Y TTM-0.35% Profit Margin17.40% Recom2.11 Target Price195.39
Option/ShortYes / Yes LT Debt/Eq0.29 EPS Q/Q6.78% Payout0.00% Rel Volume0.85 Prev Close138.45
Sales Surprise1.93% EPS Surprise3.26% Sales Q/Q6.75% EarningsFeb 12 BMO Avg Volume1.51M Price137.59
SMA20-3.40% SMA50-6.92% SMA200-27.53% Trades Volume1,222,309 Change-0.62%
Date Action Analyst Rating Change Price Target Change
Feb-11-25Initiated Bernstein Mkt Perform $160
Jan-02-25Downgrade Piper Sandler Overweight → Neutral $315 → $138
Dec-20-24Downgrade BMO Capital Markets Outperform → Market Perform $230 → $164
Dec-16-24Downgrade Stifel Buy → Hold $175
Dec-10-24Resumed BofA Securities Neutral $178
Dec-09-24Downgrade Jefferies Buy → Hold $250 → $180
Nov-18-24Downgrade Needham Buy → Hold
Nov-15-24Initiated Wolfe Research Peer Perform
Nov-14-24Initiated Citigroup Neutral $190
Oct-31-24Downgrade Morgan Stanley Overweight → Equal-Weight $285 → $204
Feb-13-25 02:30PM
10:43AM
10:33AM
07:33AM
02:08AM
12:04AM Loading…
12:04AM
Feb-12-25 11:30PM
04:18PM
01:30PM
01:13PM
10:49AM
09:51AM
09:39AM
09:30AM
08:10AM
07:41AM Loading…
07:41AM
06:47AM
06:45AM
Feb-11-25 04:28PM
01:56PM
09:49AM
08:01AM
Feb-08-25 09:20AM
Feb-07-25 09:15AM
07:32AM
Feb-05-25 10:00AM
08:16AM
Feb-02-25 08:12AM
Jan-31-25 06:30AM
Jan-29-25 12:10PM
07:28AM Loading…
Jan-28-25 07:28AM
Jan-27-25 12:40PM
09:28AM
07:12AM
07:05AM
Jan-26-25 06:38PM
06:33PM
Jan-23-25 12:06PM
09:46AM
07:30AM
Jan-22-25 12:03PM
Jan-21-25 06:05AM
Jan-15-25 06:52AM
06:26AM
Jan-14-25 06:00PM
09:41AM
09:40AM
09:04AM
08:06AM
Jan-13-25 07:05PM
03:12PM
11:57AM
09:56AM
09:51AM
09:38AM
07:24AM
07:07AM
Jan-10-25 06:49PM
06:37PM
09:02AM
06:43AM
06:25AM
Jan-09-25 08:00AM
Jan-08-25 04:40PM
Jan-04-25 07:45AM
Jan-02-25 12:03PM
09:25AM
Jan-01-25 09:40AM
09:37AM
Dec-28-24 04:49PM
Dec-23-24 05:07AM
Dec-20-24 09:44AM
Dec-16-24 01:16PM
10:26AM
Dec-13-24 08:00AM
Dec-11-24 07:10AM
Dec-09-24 01:44PM
12:27PM
Dec-05-24 08:30AM
Dec-04-24 06:31PM
Dec-02-24 07:44AM
Nov-28-24 06:08AM
Nov-27-24 07:31PM
09:15AM
Nov-26-24 02:23PM
Nov-22-24 11:00AM
07:45AM
06:45AM
Nov-20-24 01:32PM
Nov-19-24 07:06PM
01:00AM
Nov-18-24 01:18PM
11:30AM
07:00AM
04:25AM
12:40AM
Nov-14-24 02:20PM
01:53PM
01:29PM
09:54AM
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Singhal PriyaHead of DevelopmentFeb 10 '25Option Exercise0.001,21209,423Feb 12 05:48 PM
Murphy NicoleHead of Pharm Ops and TechFeb 10 '25Option Exercise0.002,272014,725Feb 12 05:47 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 10 '25Option Exercise0.003,257025,712Feb 12 05:46 PM
Kramer RobinChief Accounting OfficerFeb 10 '25Option Exercise0.0083408,257Feb 12 05:44 PM
Gregory GingerEVP, Human ResourcesFeb 10 '25Option Exercise0.002,159018,232Feb 12 05:43 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 10 '25Option Exercise0.002,575037,072Feb 12 05:42 PM
Izzar RachidHead of Global Product Strat.Feb 10 '25Option Exercise0.001,51508,998Feb 12 05:40 PM
Izzar RachidHead of Global Product Strat.Feb 07 '25Option Exercise0.003,84407,860Feb 11 09:52 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 07 '25Option Exercise0.004,551023,171Feb 10 06:59 PM
Viehbacher ChristopherPresident and CEOFeb 07 '25Option Exercise0.009,008016,008Feb 10 06:55 PM
Grogan JaneHead of ResearchFeb 07 '25Option Exercise0.001,38501,876Feb 10 06:52 PM
Keeney AdamHead of Corporate DevelopmentFeb 07 '25Option Exercise0.001,80102,463Feb 10 06:51 PM
Kramer RobinChief Accounting OfficerFeb 07 '25Option Exercise0.001,49107,667Feb 10 06:48 PM
Murphy NicoleHead of Pharm Ops and TechFeb 07 '25Option Exercise0.004,042013,056Feb 10 06:47 PM
Singhal PriyaHead of DevelopmentFeb 07 '25Option Exercise0.002,21608,892Feb 10 06:45 PM
Gregory GingerEVP, Human ResourcesFeb 07 '25Option Exercise0.003,436016,633Feb 10 06:44 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 07 '25Option Exercise0.004,130035,088Feb 10 06:42 PM
Singhal PriyaHead of DevelopmentJan 31 '25Option Exercise0.001,82807,254Feb 03 06:02 PM
Singhal PriyaHead of DevelopmentDec 06 '24Option Exercise0.0042605,742Dec 09 04:57 PM
Singhal PriyaHead of DevelopmentDec 09 '24Sale157.2111017,2935,426Dec 09 04:57 PM
Kramer RobinChief Accounting OfficerDec 06 '24Option Exercise0.0035106,578Dec 09 04:56 PM
Singhal PriyaOfficerDec 09 '24Proposed Sale157.2111017,293Dec 09 10:33 AM
Grogan JaneHead of ResearchNov 01 '24Option Exercise0.006950695Nov 04 04:39 PM
Singhal PriyaHead of DevelopmentAug 30 '24Option Exercise0.001,66806,554Sep 05 06:00 AM
Singhal PriyaHead of DevelopmentSep 03 '24Sale204.2243188,0195,316Sep 05 06:00 AM
Singhal PriyaOfficerSep 03 '24Proposed Sale204.2243188,019Sep 03 01:00 PM
Keeney AdamHead of Corporate DevelopmentMay 01 '24Option Exercise0.009380938May 03 08:00 PM
Singhal PriyaHead of DevelopmentApr 02 '24Sale213.099319,8174,886Apr 03 08:24 PM
Murphy NicoleHead of Pharm Ops and TechApr 01 '24Option Exercise0.0024009,751Apr 03 08:11 PM
Singhal PriyaHead of DevelopmentFeb 22 '24Sale221.2326257,9624,886Feb 26 07:54 PM
ALEXANDER SUSAN HEVP Chief Legal OfficerFeb 16 '24Option Exercise0.005,037052,506Feb 21 09:39 PM
Gregory GingerEVP, Human ResourcesFeb 16 '24Option Exercise0.004,704014,341Feb 21 09:36 PM
Izzar RachidHead of Global Product Strat.Feb 16 '24Option Exercise0.002,017010,014Feb 21 09:33 PM
Kramer RobinChief Accounting OfficerFeb 16 '24Option Exercise0.001,34506,354Feb 21 09:31 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 16 '24Option Exercise0.006,720020,692Feb 21 09:29 PM
Murphy NicoleHead of Pharm Ops and TechFeb 16 '24Option Exercise0.001,26009,624Feb 21 09:28 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Option Exercise0.001,20805,429Feb 21 09:27 PM
Singhal PriyaHead of DevelopmentFeb 16 '24Sale221.4910823,9215,148Feb 21 09:27 PM
Rowinsky Eric KDirectorFeb 15 '24Buy222.54455101,25620,629Feb 20 09:13 PM